Increased Number of Submacular Hemorrhages as a Consequence of Coronavirus Disease 2019 Lockdown.
作者信息
Romano Francesco, Monteduro Davide, Airaldi Matteo, Zicarelli Federico, Parrulli Salvatore, Cozzi Mariano, Staurenghi Giovanni
机构信息
Eye Clinic, Department of Biomedical and Clinical Sciences, Luigi Sacco Hospital, University of Milan, Milan, Italy.
Eye Clinic, Department of Biomedical and Clinical Sciences, Luigi Sacco Hospital, University of Milan, Milan, Italy.
出版信息
Ophthalmol Retina. 2020 Dec;4(12):1209-1210. doi: 10.1016/j.oret.2020.06.027. Epub 2020 Jun 25.
Abstract
摘要
相似文献
1
Increased Number of Submacular Hemorrhages as a Consequence of Coronavirus Disease 2019 Lockdown.
Ophthalmol Retina. 2020 Dec;4(12):1209-1210. doi: 10.1016/j.oret.2020.06.027. Epub 2020 Jun 25.
2
Ophthalmology and COVID-19: The Impact of the Pandemic on Patient Care and Outcomes: An IRIS® Registry Study.
Ophthalmology. 2021 Dec;128(12):1782-1784. doi: 10.1016/j.ophtha.2021.06.011. Epub 2021 Jun 16.
3
Sociodemographic Factors in Neovascular Age-Related Macular Degeneration.
Ophthalmology. 2020 Feb;127(2):280-282. doi: 10.1016/j.ophtha.2019.09.038. Epub 2019 Oct 4.
4
Intravitreal anti-vascular endothelial growth factor for submacular hemorrhage from choroidal neovascularization.
Ophthalmology. 2014 Apr;121(4):926-35. doi: 10.1016/j.ophtha.2013.11.004. Epub 2013 Dec 15.
5
Intravitreal ranibizumab for choroidal neovascularization with large submacular hemorrhage in age-related macular degeneration.
Retina. 2014 Feb;34(2):281-7. doi: 10.1097/IAE.0b013e3182979e33.
6
IMPACT OF CORONAVIRUS DISEASE PANDEMIC ON INTRAVITREAL INJECTIONS TREATMENT FOR MACULAR DISEASES: Report From a Referral Hospital in Milan.
Retina. 2021 Apr 1;41(4):701-705. doi: 10.1097/IAE.0000000000002941.
7
Anti-Vascular Endothelial Growth Factor Resistance in Exudative Macular Degeneration and Polypoidal Choroidal Vasculopathy.
Ophthalmol Retina. 2019 Sep;3(9):744-752. doi: 10.1016/j.oret.2019.04.018. Epub 2019 Apr 24.
8
Intravitreal Anti-Vascular Endothelial Growth Factor Use in France During the Coronavirus Disease 2019 Pandemic.
JAMA Ophthalmol. 2021 Feb 1;139(2):240-242. doi: 10.1001/jamaophthalmol.2020.5594.
9
Long-Term Changes in Submacular Choroidal Thickness after Intravitreal Ranibizumab Therapy for Neovascular Age-Related Macular Degeneration: 14-Mo Follow-Up.
Curr Eye Res. 2019 Aug;44(8):908-915. doi: 10.1080/02713683.2019.1600195. Epub 2019 Apr 16.
10
INCIDENCE AND LONG-TERM VISUAL ACUITY OUTCOMES OF RETINAL PIGMENT EPITHELIUM TEARS AFTER INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR TREATMENT OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION.
Retina. 2019 Apr;39(4):664-669. doi: 10.1097/IAE.0000000000002029.
引用本文的文献
1
Comparing visual outcomes of nAMD treatment during and after the COVID-19 restrictions period.
PLoS One. 2025 May 7;20(5):e0323253. doi: 10.1371/journal.pone.0323253. eCollection 2025.
2
Clinical outcomes in neovascular age-related macular degeneration: a cohort study of patients with care delay due to the COVID-19 pandemic.
Sci Rep. 2023 Sep 8;13(1):14814. doi: 10.1038/s41598-023-41497-4.
3
The Impact of COVID-19 on Ophthalmology Practice: Changes and Controversies in Endophthalmitis Risk.
J Ophthalmic Vis Res. 2023 Jul 28;18(3):249-251. doi: 10.18502/jovr.v18i3.13771. eCollection 2023 Jul-Sep.
4
Clinical Characteristics and Outcomes of Endophthalmitis Before and During the COVID-19 Pandemic.
J Ophthalmic Vis Res. 2023 Jul 28;18(3):289-296. doi: 10.18502/jovr.v18i3.13777. eCollection 2023 Jul-Sep.
5
Visual Outcomes of Anti-VEGF Treatment on Neovascular Age-Related Macular Degeneration: A Real-World Population-Based Cohort Study.
Pharmaceuticals (Basel). 2023 Jun 26;16(7):927. doi: 10.3390/ph16070927.
6
Impact of the COVID-19 Pandemic on Mental Health among Patients with Chronic Ocular Conditions.
Vision (Basel). 2023 Jul 11;7(3):49. doi: 10.3390/vision7030049.
7
Delaying anti-VEGF therapy during the COVID-19 pandemic: long-term impact on visual outcomes in patients with neovascular age-related macular degeneration.
BMC Ophthalmol. 2023 Apr 17;23(1):156. doi: 10.1186/s12886-023-02864-x.
8
Retinal Detachment and Laser Retinopexy Rates During the COVID-19 Pandemic.
J Vitreoretin Dis. 2020 Nov 20;5(4):295-297. doi: 10.1177/2474126420968407. eCollection 2021 Jul-Aug.
9
Choroidal Neovascularization and Macular Hemorrhage: Real-World Experience During the New York City COVID-19 Lockdown.
J Vitreoretin Dis. 2021 Feb 24;5(6):525-530. doi: 10.1177/2474126421993664. eCollection 2021 Nov-Dec.
10
Effects of COVID-19 on Intravitreal Injection Clinic After Lockdown.
Clin Ophthalmol. 2022 Sep 19;16:3089-3096. doi: 10.2147/OPTH.S358239. eCollection 2022.
本文引用的文献
1
Detrimental Effect of Delayed Re-treatment of Active Disease on Outcomes in Neovascular Age-Related Macular Degeneration: The RAMPS Study.
Ophthalmol Retina. 2020 Sep;4(9):871-880. doi: 10.1016/j.oret.2020.03.017. Epub 2020 Apr 1.
2
Academic Ophthalmology during and after the COVID-19 Pandemic.
Ophthalmology. 2020 Aug;127(8):e51-e52. doi: 10.1016/j.ophtha.2020.04.029. Epub 2020 Apr 21.
3
Reduced Rate of Hospital Admissions for ACS during Covid-19 Outbreak in Northern Italy.
N Engl J Med. 2020 Jul 2;383(1):88-89. doi: 10.1056/NEJMc2009166. Epub 2020 Apr 28.
4
A pneumonia outbreak associated with a new coronavirus of probable bat origin.
Nature. 2020 Mar;579(7798):270-273. doi: 10.1038/s41586-020-2012-7. Epub 2020 Feb 3.
5
METAANALYSIS OF REAL-WORLD OUTCOMES OF INTRAVITREAL RANIBIZUMAB FOR THE TREATMENT OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION.
Retina. 2016 Aug;36(8):1418-31. doi: 10.1097/IAE.0000000000001142.
6
Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis.
Lancet Glob Health. 2014 Feb;2(2):e106-16. doi: 10.1016/S2214-109X(13)70145-1. Epub 2014 Jan 3.
7
Natural history of macular subretinal hemorrhage in age-related macular degeneration.
Ophthalmologica. 1999;213(2):97-102. doi: 10.1159/000027400.
Zotero 插件